These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 30131584)

  • 1. Dependency on the TYK2/STAT1/MCL1 axis in anaplastic large cell lymphoma.
    Prutsch N; Gurnhofer E; Suske T; Liang HC; Schlederer M; Roos S; Wu LC; Simonitsch-Klupp I; Alvarez-Hernandez A; Kornauth C; Leone DA; Svinka J; Eferl R; Limberger T; Aufinger A; Shirsath N; Wolf P; Hielscher T; Sternberg C; Aberger F; Schmoellerl J; Stoiber D; Strobl B; Jäger U; Staber PB; Grebien F; Moriggl R; Müller M; Inghirami GG; Sanda T; Look AT; Turner SD; Kenner L; Merkel O
    Leukemia; 2019 Mar; 33(3):696-709. PubMed ID: 30131584
    [TBL] [Abstract][Full Text] [Related]  

  • 2. STAT1 is phosphorylated and downregulated by the oncogenic tyrosine kinase NPM-ALK in ALK-positive anaplastic large-cell lymphoma.
    Wu C; Molavi O; Zhang H; Gupta N; Alshareef A; Bone KM; Gopal K; Wu F; Lewis JT; Douglas DN; Kneteman NM; Lai R
    Blood; 2015 Jul; 126(3):336-45. PubMed ID: 25921060
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cytokine receptor signaling is required for the survival of ALK- anaplastic large cell lymphoma, even in the presence of JAK1/STAT3 mutations.
    Chen J; Zhang Y; Petrus MN; Xiao W; Nicolae A; Raffeld M; Pittaluga S; Bamford RN; Nakagawa M; Ouyang ST; Epstein AL; Kadin ME; Del Mistro A; Woessner R; Jaffe ES; Waldmann TA
    Proc Natl Acad Sci U S A; 2017 Apr; 114(15):3975-3980. PubMed ID: 28356514
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nucleophosmin-anaplastic lymphoma kinase: the ultimate oncogene and therapeutic target.
    Werner MT; Zhao C; Zhang Q; Wasik MA
    Blood; 2017 Feb; 129(7):823-831. PubMed ID: 27879258
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The heat shock protein-90 co-chaperone, Cyclophilin 40, promotes ALK-positive, anaplastic large cell lymphoma viability and its expression is regulated by the NPM-ALK oncoprotein.
    Pearson JD; Mohammed Z; Bacani JT; Lai R; Ingham RJ
    BMC Cancer; 2012 Jun; 12():229. PubMed ID: 22681779
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oncogenic role of miR-155 in anaplastic large cell lymphoma lacking the t(2;5) translocation.
    Merkel O; Hamacher F; Griessl R; Grabner L; Schiefer AI; Prutsch N; Baer C; Egger G; Schlederer M; Krenn PW; Hartmann TN; Simonitsch-Klupp I; Plass C; Staber PB; Moriggl R; Turner SD; Greil R; Kenner L
    J Pathol; 2015 Aug; 236(4):445-56. PubMed ID: 25820993
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic significance and therapeutic potential of the activation of anaplastic lymphoma kinase/protein kinase B/mammalian target of rapamycin signaling pathway in anaplastic large cell lymphoma.
    Gao J; Yin M; Zhu Y; Gu L; Zhang Y; Li Q; Jia C; Ma Z
    BMC Cancer; 2013 Oct; 13():471. PubMed ID: 24112608
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Crizotinib (PF-2341066) induces apoptosis due to downregulation of pSTAT3 and BCL-2 family proteins in NPM-ALK(+) anaplastic large cell lymphoma.
    Hamedani FS; Cinar M; Mo Z; Cervania MA; Amin HM; Alkan S
    Leuk Res; 2014 Apr; 38(4):503-8. PubMed ID: 24486291
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Silibinin suppresses NPM-ALK, potently induces apoptosis and enhances chemosensitivity in ALK-positive anaplastic large cell lymphoma.
    Molavi O; Samadi N; Wu C; Lavasanifar A; Lai R
    Leuk Lymphoma; 2016 May; 57(5):1154-62. PubMed ID: 26133723
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The mechanism of cancer drug addiction in ALK-positive T-Cell lymphoma.
    Rajan SS; Amin AD; Li L; Rolland DC; Li H; Kwon D; Kweh MF; Arumov A; Roberts ER; Yan A; Basrur V; Elenitoba-Johnson KSJ; Chen XS; Puvvada SD; Lussier YA; Bilbao D; Lim MS; Schatz JH
    Oncogene; 2020 Mar; 39(10):2103-2117. PubMed ID: 31804622
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-Met, in experimental models of anaplastic large-cell lymphoma.
    Christensen JG; Zou HY; Arango ME; Li Q; Lee JH; McDonnell SR; Yamazaki S; Alton GR; Mroczkowski B; Los G
    Mol Cancer Ther; 2007 Dec; 6(12 Pt 1):3314-22. PubMed ID: 18089725
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A novel model of alternative NF-κB pathway activation in anaplastic large cell lymphoma.
    Wang H; Wei W; Zhang JP; Song Z; Li Y; Xiao W; Liu Y; Zeng MS; Petrus MN; Thomas CJ; Kadin ME; Nakagawa M; Waldmann TA; Yang Y
    Leukemia; 2021 Jul; 35(7):1976-1989. PubMed ID: 33184494
    [TBL] [Abstract][Full Text] [Related]  

  • 13. IGF-IR tyrosine kinase interacts with NPM-ALK oncogene to induce survival of T-cell ALK+ anaplastic large-cell lymphoma cells.
    Shi P; Lai R; Lin Q; Iqbal AS; Young LC; Kwak LW; Ford RJ; Amin HM
    Blood; 2009 Jul; 114(2):360-70. PubMed ID: 19423729
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of differential and functionally active miRNAs in both anaplastic lymphoma kinase (ALK)+ and ALK- anaplastic large-cell lymphoma.
    Merkel O; Hamacher F; Laimer D; Sifft E; Trajanoski Z; Scheideler M; Egger G; Hassler MR; Thallinger C; Schmatz A; Turner SD; Greil R; Kenner L
    Proc Natl Acad Sci U S A; 2010 Sep; 107(37):16228-33. PubMed ID: 20805506
    [TBL] [Abstract][Full Text] [Related]  

  • 15. TYK2-STAT1-BCL2 pathway dependence in T-cell acute lymphoblastic leukemia.
    Sanda T; Tyner JW; Gutierrez A; Ngo VN; Glover J; Chang BH; Yost A; Ma W; Fleischman AG; Zhou W; Yang Y; Kleppe M; Ahn Y; Tatarek J; Kelliher MA; Neuberg DS; Levine RL; Moriggl R; Müller M; Gray NS; Jamieson CH; Weng AP; Staudt LM; Druker BJ; Look AT
    Cancer Discov; 2013 May; 3(5):564-77. PubMed ID: 23471820
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Excess of NPM-ALK oncogenic signaling promotes cellular apoptosis and drug dependency.
    Ceccon M; Merlo MEB; Mologni L; Poggio T; Varesio LM; Menotti M; Bombelli S; Rigolio R; Manazza AD; Di Giacomo F; Ambrogio C; Giudici G; Casati C; Mastini C; Compagno M; Turner SD; Gambacorti-Passerini C; Chiarle R; Voena C
    Oncogene; 2016 Jul; 35(29):3854-3865. PubMed ID: 26657151
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Activation of IGF-1R pathway and NPM-ALK G1269A mutation confer resistance to crizotinib treatment in NPM-ALK positive lymphoma.
    Li Y; Wang K; Song N; Hou K; Che X; Zhou Y; Liu Y; Zhang J
    Invest New Drugs; 2020 Jun; 38(3):599-609. PubMed ID: 31177400
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MiR-29a down-regulation in ALK-positive anaplastic large cell lymphomas contributes to apoptosis blockade through MCL-1 overexpression.
    Desjobert C; Renalier MH; Bergalet J; Dejean E; Joseph N; Kruczynski A; Soulier J; Espinos E; Meggetto F; Cavaillé J; Delsol G; Lamant L
    Blood; 2011 Jun; 117(24):6627-37. PubMed ID: 21471522
    [TBL] [Abstract][Full Text] [Related]  

  • 19. ALK kinase domain mutations in primary anaplastic large cell lymphoma: consequences on NPM-ALK activity and sensitivity to tyrosine kinase inhibitors.
    Lovisa F; Cozza G; Cristiani A; Cuzzolin A; Albiero A; Mussolin L; Pillon M; Moro S; Basso G; Rosolen A; Bonvini P
    PLoS One; 2015; 10(4):e0121378. PubMed ID: 25874976
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Convergent mutations and kinase fusions lead to oncogenic STAT3 activation in anaplastic large cell lymphoma.
    Crescenzo R; Abate F; Lasorsa E; Tabbo' F; Gaudiano M; Chiesa N; Di Giacomo F; Spaccarotella E; Barbarossa L; Ercole E; Todaro M; Boi M; Acquaviva A; Ficarra E; Novero D; Rinaldi A; Tousseyn T; Rosenwald A; Kenner L; Cerroni L; Tzankov A; Ponzoni M; Paulli M; Weisenburger D; Chan WC; Iqbal J; Piris MA; Zamo' A; Ciardullo C; Rossi D; Gaidano G; Pileri S; Tiacci E; Falini B; Shultz LD; Mevellec L; Vialard JE; Piva R; Bertoni F; Rabadan R; Inghirami G;
    Cancer Cell; 2015 Apr; 27(4):516-32. PubMed ID: 25873174
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.